Zydus Lifesciences has reported results for fourth quarter and year ended March 31, 2022.
The company has reported a fall of 46.87% in its net profit at Rs 246.90 crore for the quarter under review as compared to Rs 464.70 crore for the same quarter in the previous year. However, total income of the company increased by 4.07% at Rs 2,073 crore for Q4FY22 as compared Rs 1,991.90 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 41.47% in its net profit at Rs 397.40 crore for the quarter under review as compared to Rs 679 crore for the same quarter in the previous year. However, total income of the company increased by 8.32% at Rs 3,942.90 crore for Q4FY22 as compared Rs 3,639.90 crore for the corresponding quarter previous year.
For the year ended March 31, 2022, the company has reported a fall of 41.88% in its net profit at Rs 857.90 crore as compared to Rs 1,476.20 crore for the previous year. However, total income of the company increased by 3.70% at Rs 8,160.60 crore for year under review as compared to Rs 7,869.30 crore for year ended March 31, 2021.
For the year ended March 31, 2022, on the consolidated basis, the company has reported 2-fold jump in its net profit at Rs 4,487.30 crore as compared to Rs 2,133.60 crore for the previous year. Total income of the company increased by 7.20% at Rs 15,489.90 crore for year under review as compared to Rs 14,449.10 crore for year ended March 31, 2021.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1858.70 |
Dr. Reddys Lab | 1258.55 |
Cipla | 1559.20 |
Lupin | 2198.25 |
Zydus Lifesciences | 1004.00 |
View more.. |